Additionally, another ACC1/2 inhibitor PF-05221304, either alone or in combination with a DGAT2 (diacylglycerol O-acyltransferase 2) inhibitor, significantly reduces hepatic steatosis in patients with MASLD [99]. This evidence concerns the gene DGAT2 and metabolic dysfunction-associated steatotic liver disease.